NEEMA Web Tools

At a glance

National Center for HIV, Viral Hepatitis, STD, and TB Prevention Epidemiologic and Economic Modeling Agreement (NEEMA) supports development of web- and spreadsheet-based tools to provide state health policy makers and practitioners with information on local population sizes, disease trends, and cost projects for a variety of prevention strategies related to adolescent and school health, HIV, STIs, tuberculosis and viral hepatitis.

Tuberculosis (TB)

Tabby2

Tabby2 is a publicly available webtool based on a deterministic model for estimating tuberculosis in the United States through the year 2050. Tabby2 includes estimates for the United States, each of the 50 U.S. states, and the District of Columbia. Estimates have been adjusted to account for the 2020 decrease in tuberculosis due to the COVID-19 pandemic. Find the tool at: https://ppmltools.org/tabby2/. Tabby2's flexibility and detailed model allow for state-specific estimates of tuberculosis outcomes, related services, and costs under base-case and intervention scenarios.12

The tool also allows users to estimate the number and cost of latent tuberculosis infection (LTBI) tests, LTBI treatments, and tuberculosis disease cases, as well as the cost effectiveness of hypothetical interventions. States can use Tabby2 to set informed targets to make a compelling case to further tuberculosis elimination, and to help them plan for tuberculosis elimination.

Tabby directly reproduces numbers from Menzies et.al published in 2018. Tabby2 updates the underlying data and adds functionality to predict tuberculosis in individual states. Both Tabby and Tabby2 include predefined intervention scenarios to provide projections of tuberculosis trajectory. Custom hypothetical scenarios allow users to select health outcomes and population groups of interest and compare different scenarios.

JHSPH state tuberculosis projections for California, Florida, New York, and Texas

The tuberculosis projections tool estimates the impact and cost-effectiveness of targeted testing and treatment (TTT) for latent tuberculosis infection (LTBI) among key populations in the four most populous US states – California, Florida, New York, and Texas.3456

Caution: This tool uses pre-COVID-19 pandemic data and based on historical tuberculosis data from 1993-2013 does not reflect the current trends in tuberculosis incidence in the United States.

HIV

PrEP populations

Estimate the number of individuals indicated for PrEP. Learn more at PrEP Populations.7

Adolescent health

teen-SPARC

(STI Prevention and Risk Calculator)

This Excel-based tool is designed to assist health departments in estimating the short-term impact of behavior change on the burden of sexually transmitted infections among adolescents in their jurisdictions. Learn more at teen-SPARC.8

HCV policy simulations for prisons

HCV-PSP tool

Interactive tool that projects the cost and population health outcomes from a range of hepatitis C screening and treatment scenarios in correctional and detention facilities, using user-defined data inputs.9

The HCV Policy Simulations for Prisons (HCV-PSP) tool allows correctional and detention facilities to estimate and compare the population health benefits (including number of hepatitis C diagnoses and number of HCV infections cured) and budgetary impact of a range of strategies for hepatitis C testing and treatment in their facilities. All costs are from the facility perspective. To generate custom estimates, users can modify a set of input variables including population characteristics, intervention parameters, and costs. Learn more about the HCV-PSP tool.

Creation of web tools was supported by the US Centers for Disease Control and Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention Epidemiologic and Economic Modeling Agreement (NEEMA) PS14-1415.

Other web tools

Hep C state policy simulator

The Hep C State Policy Simulator (the Simulator) is a tool to help state heath policy makers and practitioners make decisions regarding policy, strategy, and investments related to hepatitis C. The Simulator was developed by Mass General Hospital and Harvard Medical School with support from CDC through a cooperative agreement awarded to ChangeLab Solutions. Learn more at HepCSim.

Creation of Hep C State Policy Simulator was supported by the US Centers for Disease Control and Prevention through a Cooperative Agreement number NU38OT000141.

Print
Content Source:
National Center for HIV, Viral Hepatitis, STD, and Tuberculosis Prevention
  1. Menzies NA, Cohen T, Hill AN, Yaesoubi R, Galer K, Wolf E, Marks SM, Salomon JA. Prospects for tuberculosis elimination in the United States: results of a transmission dynamic model. American Journal of Epidemiology. May 2018.
  2. Swartwood NA, Testa C, Cohen T, Marks SM, Hill AN, Beeler-Asay G, Cochran J, Cranston K, Randall LM, Tibbs A, Horsburgh CR, Salomon JA, Menzies NA. Tabby2: A User-Friendly Web Tool for Forecasting State-Level TB Outcomes in the United States. BMC Medicine. In press February 2023.
  3. Jo Y, Shrestha S, Gomes I, Marks S, Hill A, Asay G, Dowdy D. Model-based Cost-effectiveness of State-level Latent Tuberculosis Interventions in California, Florida, New York, and Texas. Clinical Infectious Diseases. 2021 Nov 2;73(9): e3476-e3482.
  4. Shrestha S, Cherng S, Hill AN, Reynolds S, Flood J, Barry PM, Readhead A, Oxtoby M, Lauzardo M, Privett T, Marks SM, Dowdy DW. Impact and Effectiveness of State-Level Tuberculosis Interventions in California, Florida, New York, and Texas: A Model-Based Analysis. American Journal of Epidemiology. 2019 Sep 1;188(9): 1733-1741.
  5. Cherng ST, Shrestha S, Reynolds S, Hill AN, Marks SM, Kelly J, Dowdy DW. Tuberculosis Incidence Among Populations at High Risk in California, Florida, New York, and Texas, 2011-2015. American Journal of Public Health. 2018 Nov;108(S4): S311-S314.
  6. Shrestha S, Hill AN, Marks SM, Dowdy DW. Comparing Drivers and Dynamics of Tuberculosis in California, Florida, New York, and Texas. Am J Respir Crit Care Med. 2017 Oct 15;196(8):1050-1059.
  7. Smith DK, Van Handel M, Grey J. Estimates of Persons with Indications for Preexposure Prophylaxis by Jurisdiction Transmission Risk Group, and Race/Ethnicity, United States, 2015. Annals of Epidemiology, 2018.
  8. Goodreau, S.M., et al., Predicting the impact of sexual behavior change on adolescent STI in the US and New York State: a case study of the teen-SPARC tool. Ann Epidemiol, 2020. 47: p. 13-18.
  9. Assoumou SA et al (2020). Cost-effectiveness and Budgetary Impact of Hepatitis C Virus Testing, Treatment, and Linkage to Care in US Prisons, Clinical Infectious Diseases, https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciz383/5490662?redirectedFrom=fulltext.